Economic Evaluation of Baroreceptor STIMulation for the Treatment of Resistant HyperTensioN (ESTIM-rHTN)
Primary Purpose
Hypertension
Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Baroreceptor stimulation with Barostim Neo TM
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension focused on measuring Hypertension, baroreceptor stimulation, Hypertension resistant
Eligibility Criteria
Main inclusion Criteria:
- 18-85 years old men or women
- Resistant hypertension on 4 medications incl. thiazide or thiazide-like diuretics at appropriate doses + spironolactone (unless spironolactone intolerance)
- Essential hypertension documented (bilan < 2 years old)
- eGFR ≥ 30 ml/min/1,73 m2
- No carotid condition associated with a contra-indication for Barostim NeoTM use
Main exclusion Criteria:
- Patients with documented secondary hypertension, besides Obstructive Sleep Apnea
- Symptomatic orthostatic hypotension
- Patient with prior syncope or myocardial infarction, unstable angina pectoris, or cerebrovascular within 3 months before inclusion
- Patient with type 1 diabetes mellitus
- Patient with permanent atrial fibrillation
- Patient with brachial circumference of ≥ 46cm
- Patient with BMI>45kg/m2
- Pregnancy, breastfeeding or planning a pregnancy within 2 years
- NeoTM implantation anatomic contra-indications
Sites / Locations
- CHU de Bordeaux
- Hôpital Arthur Gardiner
- CHU de Grenoble
- CHRU de Lille
- Hospices civils de Lyon
- APHM
- CHRU de Nancy
- APHP -Hotel Dieu hospital
- GH la Pitié Salpêtrière
- HEGP
- CHU de Poitiers
- CHU de RENNES
- CHU de Toulouse
- Clinique Pasteur
- CHRU de Tours
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
Baroreceptor stimulation on top of the best medical care
Best medical care
Arm Description
Baroreceptor stimulation with Barostim Neo TM
Best medical care
Outcomes
Primary Outcome Measures
12th month diurnal SBP (mmHg) measured on ABPM, adjusted on baseline SBP, also used to compute the incremental cost-effective ratio (to identify the extra cost of unilateral carotid barostimulation in BP reduction compared to usual care)
Secondary Outcome Measures
Mean SBP 24h on ABPM (mmHg)
Comparison with usual care
Mean nocturnal SBP on ABPM (mmHg)
Comparison with usual care
Mean DBP 24h on ABPM (mmHg)
Comparison with usual care
Mean diurnal DBP on ABPM (mmHg)
Comparison with usual care
Mean nocturnal DBP on ABPM (mmHg)
Comparison with usual care
Casual SBP (mmHg)
Comparison with usual care
Casual DBP (mmHg)
Comparison with usual care
Casual PP (mmHg)
Comparison with usual care
Pulse wave velocity (m/s)
Comparison with usual care
Central Pulse Pressure (mmHg)
Comparison with usual care
Function and Left ventricular mass on echocardiography (g/m²)
Comparison with usual care
Evolution of the kidney function (eGFR - MDRD - ml/min/1.73 m²)
Comparison with usual care
Microalbuminuria (mg/mmol creatinine)
Comparison with usual care
Antihypertensive regimen (Number of antihypertensive drugs)
Comparison with usual care
EuroQol5D (score)
Comparison with usual care
Cardiovascular events (number of events)
Comparison with usual care
Global cardiovascular risk (scale)
Comparison with usual care
Surgery Morbidity
Clavien Dindo Scale, morbidity 1 month after surgery
cerebrovascular events (number of events)
Comparison with usual care
kidney events (number of events)
Comparison with usual care
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02364310
Brief Title
Economic Evaluation of Baroreceptor STIMulation for the Treatment of Resistant HyperTensioN
Acronym
ESTIM-rHTN
Official Title
Evaluation médico-économique de la Stimulation unilatérale du Sinus Carotidien Dans le Traitement de l'Hypertension artérielle résistante: Essai Multicentrique contrôlé, randomisé, Ouvert Avec évaluation d'efficacité Tensionnelle et de sécurité
Study Type
Interventional
2. Study Status
Record Verification Date
August 2022
Overall Recruitment Status
Completed
Study Start Date
March 31, 2015 (Actual)
Primary Completion Date
June 22, 2021 (Actual)
Study Completion Date
June 22, 2021 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Pr Patrick ROSSIGNOL
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Medico-economics assessment (cost-effectiveness) of the unilateral carotid barostimulation with Barostim NeoTM compared to usual care in patients with resistant hypertension (multicenter randomized, PROBE trial), followed-up for 12 months, with a lifetime-long modeling.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
Hypertension, baroreceptor stimulation, Hypertension resistant
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
132 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Baroreceptor stimulation on top of the best medical care
Arm Type
Experimental
Arm Description
Baroreceptor stimulation with Barostim Neo TM
Arm Title
Best medical care
Arm Type
No Intervention
Arm Description
Best medical care
Intervention Type
Device
Intervention Name(s)
Baroreceptor stimulation with Barostim Neo TM
Primary Outcome Measure Information:
Title
12th month diurnal SBP (mmHg) measured on ABPM, adjusted on baseline SBP, also used to compute the incremental cost-effective ratio (to identify the extra cost of unilateral carotid barostimulation in BP reduction compared to usual care)
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Mean SBP 24h on ABPM (mmHg)
Description
Comparison with usual care
Time Frame
6 and 12 months
Title
Mean nocturnal SBP on ABPM (mmHg)
Description
Comparison with usual care
Time Frame
6 and 12 months
Title
Mean DBP 24h on ABPM (mmHg)
Description
Comparison with usual care
Time Frame
6 and 12 months
Title
Mean diurnal DBP on ABPM (mmHg)
Description
Comparison with usual care
Time Frame
6 and 12 months
Title
Mean nocturnal DBP on ABPM (mmHg)
Description
Comparison with usual care
Time Frame
6 and 12 months
Title
Casual SBP (mmHg)
Description
Comparison with usual care
Time Frame
6 and 12 months
Title
Casual DBP (mmHg)
Description
Comparison with usual care
Time Frame
6 and 12 months
Title
Casual PP (mmHg)
Description
Comparison with usual care
Time Frame
6 and 12 months
Title
Pulse wave velocity (m/s)
Description
Comparison with usual care
Time Frame
6 and 12 months
Title
Central Pulse Pressure (mmHg)
Description
Comparison with usual care
Time Frame
6 and 12 months
Title
Function and Left ventricular mass on echocardiography (g/m²)
Description
Comparison with usual care
Time Frame
6 and 12 months
Title
Evolution of the kidney function (eGFR - MDRD - ml/min/1.73 m²)
Description
Comparison with usual care
Time Frame
6 and 12 months
Title
Microalbuminuria (mg/mmol creatinine)
Description
Comparison with usual care
Time Frame
6 and 12 months
Title
Antihypertensive regimen (Number of antihypertensive drugs)
Description
Comparison with usual care
Time Frame
6 and 12 months
Title
EuroQol5D (score)
Description
Comparison with usual care
Time Frame
6 and 12 months
Title
Cardiovascular events (number of events)
Description
Comparison with usual care
Time Frame
baseline, 6 and 12 months
Title
Global cardiovascular risk (scale)
Description
Comparison with usual care
Time Frame
6 and 12 months
Title
Surgery Morbidity
Description
Clavien Dindo Scale, morbidity 1 month after surgery
Time Frame
1 month
Title
cerebrovascular events (number of events)
Description
Comparison with usual care
Time Frame
baseline, 6 and 12 months
Title
kidney events (number of events)
Description
Comparison with usual care
Time Frame
baseline, 6 and 12 months
Other Pre-specified Outcome Measures:
Title
Cost of unilateral carotid barostimulation including hospital stay
Time Frame
participants will be followed for the duration of hospital stay, an expected average of 2 days
Title
ICER: difference in cost / difference in office systolic blood pressure (SBP) in mmHg
Time Frame
12 months
Title
ICER/ICER: difference in cost / difference in QALY (quality-of-life-adjusted survival based on the clinical trial data and the modeling results) for the lifetime modeling
Time Frame
12 months
Title
Budget impact (cost in Euros)
Time Frame
4 years
Title
Number of outpatient visits for hypertension management in both groups
Time Frame
12 months
Title
Morbidity
Description
Tolerance
Time Frame
6 and 12 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Main inclusion Criteria:
18-85 years old men or women
Resistant hypertension on 4 medications incl. thiazide or thiazide-like diuretics at appropriate doses + spironolactone (unless spironolactone intolerance)
Essential hypertension documented (bilan < 2 years old)
eGFR ≥ 30 ml/min/1,73 m2
No carotid condition associated with a contra-indication for Barostim NeoTM use
Main exclusion Criteria:
Patients with documented secondary hypertension, besides Obstructive Sleep Apnea
Symptomatic orthostatic hypotension
Patient with prior syncope or myocardial infarction, unstable angina pectoris, or cerebrovascular within 3 months before inclusion
Patient with type 1 diabetes mellitus
Patient with permanent atrial fibrillation
Patient with brachial circumference of ≥ 46cm
Patient with BMI>45kg/m2
Pregnancy, breastfeeding or planning a pregnancy within 2 years
NeoTM implantation anatomic contra-indications
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Patrick ROSSIGNOL, Prof
Organizational Affiliation
CHRU Nancy
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Michel AZIZI, Prof
Organizational Affiliation
APHP-HEGP
Official's Role
Principal Investigator
Facility Information:
Facility Name
CHU de Bordeaux
City
Bordeaux
Country
France
Facility Name
Hôpital Arthur Gardiner
City
Dinard
Country
France
Facility Name
CHU de Grenoble
City
Grenoble
Country
France
Facility Name
CHRU de Lille
City
Lille
Country
France
Facility Name
Hospices civils de Lyon
City
Lyon
Country
France
Facility Name
APHM
City
Marseille
Country
France
Facility Name
CHRU de Nancy
City
Nancy
Country
France
Facility Name
APHP -Hotel Dieu hospital
City
Paris
ZIP/Postal Code
75000
Country
France
Facility Name
GH la Pitié Salpêtrière
City
Paris
Country
France
Facility Name
HEGP
City
Paris
Country
France
Facility Name
CHU de Poitiers
City
Poitiers
Country
France
Facility Name
CHU de RENNES
City
Rennes
ZIP/Postal Code
35033
Country
France
Facility Name
CHU de Toulouse
City
Toulouse
Country
France
Facility Name
Clinique Pasteur
City
Toulouse
Country
France
Facility Name
CHRU de Tours
City
Tours
Country
France
12. IPD Sharing Statement
Learn more about this trial
Economic Evaluation of Baroreceptor STIMulation for the Treatment of Resistant HyperTensioN
We'll reach out to this number within 24 hrs